REPLY: Cangrelor or Abciximab as First Choice in Cardiogenic Shock

Journal article

Peer reviewed

Muthiah Vaduganathan, Arman Qamar, Hisham A. Badreldin, David P. Faxon and Deepak L. Bhatt

JACC. Cardiovascular interventions, Vol.10(23), pp.2468-2469

11/12/2017

PMID: 29217013

Abstract

Cardiac & Cardiovascular Systems

Cardiovascular System & Cardiology

Life Sciences & Biomedicine

Science & Technology

1 Record Views

Title: REPLY: Cangrelor or Abciximab as First Choice in Cardiogenic Shock
Creators - without role: Muthiah Vaduganathan
Arman Qamar
Hisham A. Badreldin
David P. Faxon
Deepak L. Bhatt - Brigham and Women's Hospital
Publication Details: JACC. Cardiovascular interventions, Vol.10(23), pp.2468-2469
Publisher: Elsevier
Number of pages: 3
Grant note: AstraZeneca Ironwood Pfizer Bristol-Myers Squibb Chiesi; Chiesi Pharmaceuticals Inc T32HL007604 / National Heart, Lung, and Blood Institute T32 postdoctoral training grant Ischemix Lilly; Eli Lilly Forest Laboratories the Medicines Company Eisai; Eisai Co Ltd Amarin Medtronic Ethicon Amgen Sanofi Roche; Roche Holding
Identifiers: 9921065908331
Academic Unit: King Abdulaziz University; King Saud Bin Abdulaziz University for Health Sciences
Language: English
Resource Type: Journal article